Human FcRn / FCGRT&B2M Heterodimer Protein, His Tag (SPR & BLI & MALS verified)
分子别名（Synonym）
FcRn, FCGRT & B2M
表达区间及表达系统（Source）
Human FCGRT&B2M Heterodimer Protein, His Tag (FCN-H52W7) is expressed from human 293 cells (HEK293). It contains AA Ala 24 - Ser 297 (FCGRT) & Ile 21 - Met 119 (B2M) (Accession # P55899-1 (FCGRT) & P61769-1 (B2M)).
Predicted N-terminus: Ala 24 (FCGRT) & Ile 21 (B2M)
蛋白结构（Molecular Characterization）
Human FCGRT&B2M Heterodimer Protein, His Tag, produced by co-expression of FCGRT and B2M, has a calculated MW of 32.3 kDa (FCGRT) and 11.7 kDa (B2M). Subunit FCGRT is fused with a polyhistidine tag at the C-terminus and subunit Beta-2 microglobulin (B2M) contains no tag at the C-terminus. The reducing (R) protein migrates as 33 kDa (FCGRT) and 10 kDa (B2M) respectively due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景介绍
FCGRT与B2M异源二聚体蛋白（FcRn复合物）由两个亚基组成：p51（即FCGRT）和p14（即β2-微球蛋白），共同构成MHC I类样异源二聚体结构。该复合物中，IgG Fc片段受体转运蛋白α亚基（FCGRT）可结合单体免疫球蛋白γ的Fc区域，介导乳汁中IgG的摄取过程，并可能参与母胎间免疫球蛋白G的转运。另一亚基β2-微球蛋白（B2M）作为主要组织相容性复合体I类分子（MHC I）的关键组分，通过MHC I类分子参与向免疫系统呈递肽类抗原的过程。
关键字： FcRn (FCGRT & B2M);FCGRT蛋白;B2M重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。